Product description
What is TB-500?
TB-500 is a synthetic peptide that is a functional analog of naturally occurring thymosin beta-4 (Tβ4) – a 43-amino-acid polypeptide originally discovered in bovine thymus in 1981. TB-500 contains the key actin-binding sequence (LKKTETQ) responsible for the parent protein's main biological effects, with N-terminal acetylation increasing stability.
Thymosin β4 is one of the most abundant intracellular proteins in mammals, present at high concentrations in all tissues except erythrocytes. Particularly high levels are found in platelets, leukocytes, wound exudate, and macrophages – all elements involved in repair processes.
TB-500 was originally developed for veterinary use (mainly in horse racing) and gained notoriety in the 2010s as a peptide allegedly used to improve performance and recovery in racehorses.
Mechanism of action
The primary mechanism of action of TB-500/Tβ4 is based on the regulation of actin dynamics and its consequences for cellular processes:
G-actin binding and sequestration – TB-500 binds with high affinity to monomeric G-actin (globular actin), forming a 1:1 complex. This binding prevents the spontaneous polymerization of G-actin into F-actin (filamentous actin) and regulates monomer availability for controlled cytoskeletal remodeling. G-actin sequestration is crucial for cell migration, changes in cell shape, and cell division.
Promotion of cell migration – By regulating actin, TB-500 increases cells' ability to migrate toward the site of injury. This effect applies to many cell types: keratinocytes, fibroblasts, endothelial cells, myoblasts, and stem/progenitor cells.
Stimulation of angiogenesis – TB-500 promotes the formation of new blood vessels by stimulating endothelial cell migration, the formation of capillary-like structures, and an increase in microvessel density in tissues. This mechanism is particularly important for healing poorly vascularized tissues (tendons, cartilage).
Anti-inflammatory effect – The sulfoxide form of thymosin β4 (Tβ4-SO) blocks neutrophil chemotaxis and shows anti-inflammatory activity in vivo. TB-500 inhibits the release of pro-inflammatory cytokines and may modulate NF-κB activity.
Anti-apoptotic effect – TB-500 protects cells from apoptosis by increasing BCL-2 expression and decreasing caspase activation, partly by preventing cytochrome c release from mitochondria.
Reduction of fibrosis – In wound-healing processes, TB-500 reduces the number of myofibroblasts, leading to less scar formation and fibrosis. This mechanism is important for preserving the functionality of regenerating tissues.
Research directions
Thymosin β4 (and its synthetic analog TB-500) is the subject of extensive preclinical research and limited clinical studies.
Wound-healing research
The seminal study by Philp et al. (1999) showed that topical or intraperitoneal administration of Tβ4 accelerated wound re-epithelialization in rats by 42% after 4 days and by as much as 61% after 7 days compared with controls. Tβ4-treated wounds also showed increased contraction, greater collagen deposition, and enhanced angiogenesis. In in vitro studies, Tβ4 stimulated keratinocyte migration 2- to 3-fold at concentrations as low as 10 pg. These effects were confirmed in diabetic (db/db) and aged mice, where a 7-amino-acid synthetic peptide based on the actin-binding domain (equivalent to TB-500) promoted repair comparable to the full parent molecule.
Muscle regeneration research
Studies by Hary et al. showed that Tβ4 acts as a chemoattractant for myoblasts (muscle precursor cells). Tβ4 and thymosin β10 mRNA levels are elevated in the early stages of skeletal muscle regeneration in mice. Both Tβ4 and its sulfoxide form accelerated wound closure and increased chemotaxis of the C2C12 myoblast line as well as primary myoblasts and myocytes derived from satellite cells of adult mouse muscle.
Cardiology research
Thymosin β4 is expressed in the developing heart and adult myocardium (endothelium, epicardium, coronary vascular endothelium). Preclinical studies in myocardial infarction models have shown:
- Improved left ventricular function
- Reduced infarct size
- Reduced cardiomyocyte death
- Increased cardiac microvessel density
- Improved long-term cardiac remodeling
The mechanism involves promotion of cardiac angiogenesis, reduction of inflammatory damage, and stimulation of cardiomyocyte survival pathways.
Ophthalmology research
Thymosin β4 is being intensively studied in the context of corneal wound healing and Pseudomonas aeruginosa-induced keratitis. The peptide shows anti-inflammatory activity by inhibiting NF-κB in corneal endothelial cells. Phase II clinical studies with Tβ4 in corneal regeneration have been conducted.
Sepsis research
In septic states, elevated levels of free F-actin are observed in the blood (F-actinemia), which can damage the endothelium and form microthrombi. Tβ4, as an actin-binding protein, inhibits F-actin polymerization and is being investigated as a potential protective factor in sepsis.
Dermatology research – clinical studies
In phase II clinical studies, Tβ4 (RGN-259, RegeneRx Biopharmaceuticals) promoted healing of venous stasis ulcers and showed potential in the treatment of epidermolysis bullosa and other severe skin injuries.
Scientific context
TB-500/Thymosin β4 fits into the concept of „reminding adult organs of their embryonic state” – the peptide plays a key role in the embryonic development of the heart, brain, eyes, and limbs, and its exogenous administration can reactivate regenerative processes in adult tissues.
Compared with other regenerative peptides:
- BPC-157 – a gastric pentadecapeptide, stable in the gastric environment, acting mainly through modulation of the NO system and the VEGFR2 pathway
- TB-500 – a fragment of thymosin β4, acting through actin regulation and promotion of cell migration, unstable in the gastric environment
These two peptides are often used together by researchers because of their complementary mechanisms of action – TB-500 promotes cell migration to the site of injury, while BPC-157 supports angiogenesis and modulates signaling pathways.
Thymosin β4 and TB-500 are included on the WADA Prohibited List as substances that promote tissue regeneration and may potentially enhance athletic performance.
Safety profile in research
In preclinical studies, thymosin β4 showed a favorable safety profile without significant toxic effects. The peptide is a natural component of the body, present at high concentrations in many tissues.
In limited clinical studies (mainly dermatological and ophthalmological), no serious adverse events associated with the therapy were reported.
Potential theoretical concerns:
- Promotion of angiogenesis raises the theoretical question of an effect on the progression of malignant tumors, although there is no clinical evidence of increased risk
- As an exogenous peptide, TB-500 may potentially trigger immunogenic reactions
- The long-term safety profile with systemic administration in humans remains unknown
Bibliography – latest scientific research
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed
- Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004;18(2):385-387. PubMed
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PubMed
- Huff T, Müller CS, Otto AM, et al. Beta-thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. PubMed
- Maar K, Hetenyi R, Maar S, et al. Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies. Cells. 2021;10(6):1343. PMC
- Ho ENM, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta(4), in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed
- Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol. 2007;1(3):201-207. PMC
- Philp D, Badamchian M, Scheremeta B, et al. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. PubMed
- Kleinman HK, Sosne G. Thymosin beta4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-275. PubMed
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B. 2024;1235:124033. PubMed
